The prognostic significance of CD63 expressionin patients with non-small cell lung cancer

Hyun Koh; Hyo An; Jae Jung; Dae Song

doi:10.5114/pjp.2019.90394

eISSN: 2084-9869
ISSN: 1233-9687

Polish Journal of Pathology

Current issue Archive Manuscripts accepted About the journal Supplements Editorial board Abstracting and indexing Subscription Contact Instructions for authors Publication charge Ethical standards and procedures

Editorial System

Submit your Manuscript

Editorial Policies

Sarajevo Declaration on Integrity and Visibility of Scholarly Publications

Open access

3/2019
vol. 70

Send email

Copy url:

abstract:

Original paper

The prognostic significance of CD63 expressionin patients with non-small cell lung cancer

Hyun Min Koh

¹

,

Hyo Jung An

¹

,

Jae Jun Jung

²

,

Dae Hyun Song

^{1, 3, 4}

Department of Pathology, Gyeongsang National University Changwon Hospital, South Korea

Department of Thoracic and Cardiovascular Surgery, Gyeongsang National University Changwon Hospital, South Korea

Gyeongsang National University School of Medicine, South Korea

Gyeongsang Institute of Health Science, South Korea

Pol J Pathol 2019; 70 (3): 183-188

DOI: https://doi.org/10.5114/pjp.2019.90394

Online publish date: 2019/12/08

View full text Get citation

PlumX metrics:

CD63 has been suggested to participate in tumorigenesis, invasion, and metastasis. In this study, we aimed to investigate the prognostic significance of CD63 expression in non-small cell lung cancer (NSCLC).

CD63 expression was evaluated in 133 cases of NSCLC via immunohistochemical staining using tissue microarray blocks. We assessed the relationship between CD63 expression and clinicopathological characteristics, as well as the prognostic significance of CD63 expression in NSCLC.

CD63 expression was significantly correlated with patient gender (p < 0.001), smoking history (p = 0.020), histologic type (p < 0.001), tumour stage (p = 0.016), lymph node metastasis (p = 0.034), and TNM stage (p = 0.007). A multivariate Cox proportional hazards regression analysis determined low CD63 expression to be an independent factor for unfavourable disease-free survival (DFS) (HR = 2.043, 95% CI: 1.035-4.035, p = 0.040), and Kaplan-Meier analysis indicated that the low CD63 expression group showed significantly lower DFS than the high CD63 expression group of patients with NSCLC (p = 0.019).

Low CD63 expression might be an unfavourable prognostic factor in patients with NSCLC.

keywords:

The prognostic significance of CD63 expressionin patients with non-small cell lung cancer

Hyun Min Koh 1 , Hyo Jung An 1 , Jae Jun Jung 2 , Dae Hyun Song 1, 3, 4

carcinoma, CD63, lung, non-small cell, prognosis

Hyun Min Koh

¹

,

Hyo Jung An

¹

,

Jae Jun Jung

²

,

Dae Hyun Song

^{1, 3, 4}